Erik C. Michelfelder

One-Year Follow-Up of the Amplatzer Device to Close Atrial Septal Defects

The early and 1-year follow-up of a single United States center using the Amplatzer atrial septal defect closure device is reported. Complete closure was documented in all patients by 1 year after device implantation.

Exposure to ionizing radiation in children undergoing amplatzer device placement to close atrial septal defects

To evaluate exposure to ionizing radiation during Amplatzer device occlusion, a prospective study was performed to measure surface entrance radiation dose by thermoluminescent dosimetry (TLD). Between June 1998 and April 1999, dosimetry was carried out on 12 patients with Amplatzer device occlusion of atrial septal defects (n = 10) or Fontan fenestration (n =) and 12 age‐matched patients who underwent diagnostic catherization. TLD chips were placed at the posterior (PA) and right lateral (LA) chest wall as well as the thyroid (TH) and gonadal (GN) regions. The Amplatzer group had a median age of 6.4 yr (2.4–12.4 yr) and a median weight of 23.7 kg (15.6–28.9 kg), which were similar (p = NS) to those of the control group, who had a median age of 7.9 yr (3.3–16.2 yr) and a median weight of 29.9 kg (10.6–58.0 kg). Device placement was successful in 11 of 12 patients; one device was removed owing to partial obstruction of the right‐upper pulmonary vein. Fluoroscopy times were also similar in the Amplatzer group (23.5 ± 2.1 min) and the control group (16.4 ± 3.1 min; P = NS). The measured surface entrance doses of the Amplatzer group was similar (p = NS) to those of the control group in all four regions: PA (4.96 ± 1.88 vs. 6.07 ± 2.16 cGy), LA (5.22 ± 1.68 vs. 3.13 ± 1.25 cGy), TH (0.92 ± 0.14 vs. 0.69 ± 0.09 cGy), and GN (0.20 ± 0.00 vs. 0.22 ± 0.01cGy). Fluoroscopy times and measured surface entrance doses of ionizing radiation in patients undergoing Amplatzer device occlusion are similar to those in patients undergoing routine diagnostic catheterization. Cathet. Cardiovasc. Intervent. 51:451–454, 2000.

PERINATAL OUTCOMES AFTER FETAL DIAGNOSIS OF EBSTEIN ANOMALY OR TRICUSPID VALVE DYSPLASIA IN THE CURRENT ERA: A MULTI-CENTER STUDY

Ebstein anomaly and tricuspid valve dysplasia (EA/TVD) are rare congenital tricuspid valve malformations associated with high perinatal mortality. The literature to date consists of small, single center case series often spanning several decades. We performed a multi-center study to assess perinatal